FDAnews Device Daily Bulletin

Biologica Technologies Launches Allofill Injectable Adipose Filler

Sept. 26, 2016

Biologica Technologies announced the launch of its Allofill device during the American Society of Plastic Surgeons conference in Los Angeles.

Allofill is a ready-to-use, adipose-derived injectable filler that works with the body to provide an all-natural tissue scaffold with native growth factors.  Allofill retains the native extracellular matrix (ECM) components of allograft-derived adipose tissue and over time will be remodeled into a patient's own soft tissue.

This allograft product provides higher growth factors than a standard autologous fat transfer and is more natural than an HA, or similar, dermal filler, Biologica said. — Cynthia Jessup

View today's stories